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suggest hat an important mechanism for the actions of Fluosol is 
through alteration of various neutrophil functions. Although we can- 
not completely eliminate a role for hyperoxic reperfusion or other 
actions in the beneficial effects of Fluosol (8), the current study does 
not support the finding that hyperoxic reperfusion is the primary 
mechanism or that the effects of Fluosol are not mediated through 
neutrophils. 
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Reply 
Murray et al. raise several questions concerning the methodologies 
used in our assessment of polymorphonuclear leukocyte (PMN) func- 
tion (1). As Murray et al, point out, previous in vitro evidence supports 
the premise that the detergent component of Fluosol-DA, poloxamer 
188, dfrectly activates PMNs through phagocytosis (2). In light of these 
findings, these investigators propose that either Fluosol-DA or polox- 
amer 188 activate PMNs while in circulation. Activated PMNs would 
thus be refractory to subsequent stimulation and lose their ability to 
promote infarct extension upon reperfusion (2). Murray et al. take 
issue with our study because we exposed PMNs to cytochalasin B (an 
agent that blocks phagocytosis) before assessment of their function. 
Cytochalasin B is commonly used in PMN superoxide assays because it 
enhances both the rate and amount of superoxide anion ('O2-) 
production. This effect most likely occurs by inhibiting phagocytic 
vacuole formation, which prevents the access of cell surface-generated 
superoxide anion to cytoplasmic superoxide dismutase. Therefore, 
more superoxide anion is exposed to the detector chromogen ferricy- 
tochrome C (3). 
In our study, PMNs were pretreated with cytochalasin B for 
superoxide anion and lysozyme release assays. The PMNs were 
isolated at 3 h of reperfusion only after exposing the ischemic 
reperfused animal to Flnosol-DA or poloxamer 188 in vivo. For 
chemotaxis assays, PMNs were not pretreated with cytochalasin B
because it prevents the polymerization of actin and therefore would 
impair chemotactic responses (4). If the hypothesis proposed by 
Murray et al. is correct, one would expect that PMNs isolated after 
treating rabbits with Fluosol-DA and poloxamer in vivo would exhibit 
"burnout" and resistance to stimulation. This was clearly not the case; 
PMNs from Fluosol-DA- and poloxamer 188-treated rabbits re- 
sponded equally as well or better than control or sham operated 
(noninfarcted) animals (unpublished observations) to receptor- 
mediated activation. Furthermore, the myocardial myeloperoxidase 
content between groups was similar, suggesting that the degree of 
PMN infiltration in the ischemic region was not influenced by treat- 
ment. 
We disagree with the comment by Murray et al. that the dose of 
Fluosol-DA used in the study (20 mg/ml) was not high enough to 
demonstrate changes in PMN function. The efficacy of this concentra- 
tion of Fluosol-DA to reduce infarct size was demonstrated both in the 
present study in question and in a previous tudy in our laboratory (5). 
With regard to the poloxamer infarct size data, a recent study by 
Schaer et al. (6) utilizing the canine infarct model failed to demon- 
strate infarct size reduction with poloxamer 188 in normoxic reper- 
fused hearts when it was administered as an intravenous bolus followed 
by a 4-h infusion, which is consistent with the finding in the present 
study (1). However, infarct size reduction was significantly reduced 
after a prolonged 48-h infusion of poloxamer 188 (6). Although in vitro 
treatment of PMNs with poloxamer 188 enhanced superoxide anion 
production and suppressed chemotaxis (6), this agent also has hemo- 
rheologic properties eparate from neutrophil effects that may affect 
infarct size after reperfusion. 
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